Extraglandular Manifestations Beyond Dryness

Key Takeaways:

• Sjögren's disease is systemic, with articular, cutaneous, pulmonary, neurologic, renal, and hematologic involvement.
• Published prevalence figures vary widely by organ, mostly because studies switch between symptom-level and organ-damage definitions – and because some report percentages of an affected subgroup rather than of all patients.
• Extraglandular involvement can precede sicca symptoms entirely, which is one reason recognition is delayed.

The sicca-only mental model of Sjögren's disease is the main obstacle to recognizing it as a systemic disease. Two mechanisms operate in parallel. Lymphocytic infiltration of epithelia beyond the exocrine glands produces interstitial nephritis, primary biliary cholangitis, and obstructive bronchiolitis.¹

Immune-complex deposition arising from ongoing B-cell hyperreactivity produces a different, extraepithelial set:¹

• Palpable purpura
• Cryoglobulinemia-associated glomerulonephritis
• Interstitial pneumonitis
• Peripheral neuropathy

Neither set resembles dry eyes and dry mouth. Note that the prevalence figures below come from cohorts of primary disease unless stated otherwise.

A domain-based frame

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) organizes systemic activity across 12 organ domains:²

• Constitutional
• Lymphadenopathy
• Glandular
• Articular
• Cutaneous
• Pulmonary
• Renal
• Muscular
• Peripheral nervous system
• Central nervous system
• Hematological
• Biological

Its value in the clinic is less as a score than as a checklist – a systematic pass through organ systems that a symptom-led review will skip. It is also the vehicle through which extraglandular disease enters routine assessment at all, and the 2016 classification criteria use a positive ESSDAI domain as an alternative eligibility route for patients without sicca complaints.³

Reading the prevalence spread

Per-organ figures in the literature diverge more than they should, and knowing why makes them usable. Musculoskeletal involvement illustrates it. Arthralgia is reported in up to 96% of patients and arthritis in 17%.⁴

The ESSDAI articular domain – which requires arthralgia with morning stiffness, or synovitis, rather than either alone – was met by 38% in a classification of more than 10,000 patients across 22 countries. Those are not competing estimates but 3 definitions, and the middle one is what a domain-based assessment actually records.¹

The same distinction governs the headline figure. Systemic manifestations are reported in approximately 30 to 40% of patients when a cohort is classified by ESSDAI domain.1

Reviews describing the disease course put it higher, holding that most patients develop extraglandular manifestations as the disease progresses. Point prevalence and lifetime accrual are different quantities, and the distance between them is why a single reassuring visit is weak evidence.⁴

Cutaneous involvement is reported in up to 72% of patients, with xeroderma reported at the same 72% and eyelid dermatitis at 42%. Raynaud phenomenon appears in 16 to 35% and cutaneous vasculitis lesions in 10 to 30%, of which palpable purpura accounts for 80 to 90%.⁴

Vasculitis is the cutaneous finding that matters prognostically. It is associated with more severe systemic disease and with lymphoma, and roughly a third of affected patients have positive cryoglobulins.⁴

Neurologic figures require the most care, because published tables switch denominators mid-column. Central nervous system involvement is reported in about 5% of patients and peripheral nervous system involvement in 4 to 16%.⁴

Figures such as cognitive dysfunction in 53% or cranial neuropathy in 16 to 20% are percentages of the patients with central involvement, not of all patients with Sjögren's – an important distinction, since the unqualified version overstates by an order of magnitude. The same applies to the pure sensory and sensorimotor neuropathy proportions, which are shares of the peripheral-involvement subgroup.⁴

When organ disease arrives first

Pulmonary involvement is the clearest case for looking before being asked. Consensus guidelines put respiratory involvement at 10 to 20% of patients, note chronic cough in around 38%, and cite a study in which up to 65% of asymptomatic patients had abnormal pulmonary imaging.⁵

On that basis, the guidelines direct clinicians to obtain a detailed respiratory history at the initial and every subsequent visit, at high strength of evidence and strong strength of recommendation. The reverse also holds: In patients without an established Sjögren's diagnosis, unexplained cough with dry eyes led to confirmation of Sjögren's in 36%.⁵

That sequence is not unusual. Among 276 respondents to a survey of a Japanese patient association – a cohort spanning both primary and associated disease – 40% reported neither dry eye nor dry mouth at their first medical visit, against 87% reporting both by the time of the survey. Dryness accrues; a patient can be well into organ involvement before the symptom that names the disease appears.⁶

The practical consequence is a short list of findings that should prompt reassessment rather than reassurance: new palpable purpura, unexplained peripheral sensory symptoms, an unexplained chronic cough, and non-destructive inflammatory arthralgia without a competing explanation. Each sits in a different ESSDAI domain, and none begins with dryness.